Clinical Trial

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Terminated Phase 1/2
View on ClinicalTrials.gov →
Why the trial stopped
Strategic decision by Sponsor.
Summary
In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab) .
Protocol Amendment History 4 changes
critical Trial terminated 2026-07-24
notable Enrollment reduced: 204 -> 12 participants 2026-07-24
notable Primary completion moved earlier: 2028-08 -> 2025-01-13 2026-07-24
minor Completion moved earlier: 2028-08 -> 2025-01-13 2026-07-24
Trial Details
NCT Number NCT06022757
Lead Sponsor Evopoint Biosciences Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Prostate Cancer, Small-cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Other Solid Tumors
Enrollment 12 participants
Start Date 2023-09-20
Primary Completion 2025-01-13 (estimated)
Study Completion 2025-01-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-23